Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source - Episode 2
Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
Published on:
A expert cardiologist delves into the insights gained from clinical trials assessing Cardiac Myosin inhibitors (CMIs) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a particular focus on the EXPLORER-HCM trial, which investigated the efficacy and safety of mavacamten in managing oHCM.
- What have we learned from clinical trials evaluating CMI’s for oHCM? Hutt et al 2024
- Mavacamten: Outcomes; focused on feel and function Olivotto et al 2020, Maron et al 2023
- Longer-term outcomes of the VALOR-HCM RCT Desai et al 2023
- MAVA-LTE
- Aficamten: phase 2 REDWOOD-HCM soon to be completed, phase 3 trial SEQUIOA-HCM. Masri et al 2022, Maron et al 2023
